R
Raman Desikan
Researcher at University of Arkansas for Medical Sciences
Publications - 27
Citations - 5677
Raman Desikan is an academic researcher from University of Arkansas for Medical Sciences. The author has contributed to research in topics: Multiple myeloma & Thalidomide. The author has an hindex of 18, co-authored 26 publications receiving 5527 citations. Previous affiliations of Raman Desikan include Celgene.
Papers
More filters
Journal ArticleDOI
Antitumor activity of thalidomide in refractory multiple myeloma.
Seema Singhal,Jayesh Mehta,Raman Desikan,D Ayers,Paula K. Roberson,Paul Eddlemon,Nikhil C. Munshi,Elias Anaissie,Carla S. Wilson,Madhav V. Dhodapkar,J Zeddis,Bart Barlogie +11 more
TL;DR: Thalidomide can induce marked and durable responses in some patients with multiple myeloma, including those who relapse after high-dose chemotherapy, and is active against advancedMyeloma.
Journal ArticleDOI
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.
Bart Barlogie,Raman Desikan,Raman Desikan,Paul Eddlemon,Paul Eddlemon,Trey Spencer,Trey Spencer,Jerome B. Zeldis,Jerome B. Zeldis,Nikhil C. Munshi,Nikhil C. Munshi,Ashrof Badros,Ashrof Badros,Maurizio Zangari,Maurizio Zangari,Elias Anaissie,Elias Anaissie,Joshua Epstein,Joshua Epstein,John D. Shaughnessy,John D. Shaughnessy,Dan Ayers,Dan Ayers,D. Spoon,D. Spoon,Guido J Tricot,Guido J Tricot +26 more
TL;DR: Response rates were higher and survival was longer especially in high-risk patients given more than 42 g THAL in 3 months (median cumulative dose) (landmark analysis); this supports a THAL dose-response effect in advanced MM.
Journal ArticleDOI
Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.
Maurizio Zangari,Elias Anaissie,Bart Barlogie,Ashraf Badros,Raman Desikan,A. Viju Gopal,Christopher Morris,Amir A. Toor,Eric R. Siegel,Louis M. Fink,Guido Tricot +10 more
TL;DR: Thalidomide given in combination with multiagent chemotherapy and dexamethasone is associated with a significantly increased risk of deep-vein thrombosis, which appears to be safely treated with anticoagulation and does not necessarily warrant discontinuation of thalidomides.
Journal ArticleDOI
Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities.
Raman Desikan,Bart Barlogie,Bart Barlogie,Jeffrey Sawyer,Jeffrey Sawyer,Dan Ayers,Dan Ayers,Guido J Tricot,Guido J Tricot,Ashraf Badros,Ashraf Badros,Maurizio Zangari,Maurizio Zangari,Nikhil C. Munshi,Nikhil C. Munshi,Elias Anaissie,Elias Anaissie,D. Spoon,D. Spoon,David S. Siegel,David S. Siegel,Sundar Jagannath,Sundar Jagannath,David H. Vesole,David H. Vesole,Joshua Epstein,Joshua Epstein,John D. Shaughnessy,John D. Shaughnessy,Athanasios Fassas,Athanasios Fassas,Seah Lim,Seah Lim,Paula Roberson,Paula Roberson,John Crowley,John Crowley +36 more
TL;DR: CR and a second HDT cycle applied within 6 months both extended event-free and overall survival significantly, justifying further pursuit of HDT, especially toward curing non-triangle up13 MM.
Journal ArticleDOI
Results of autologous stem cell transplant in multiple myeloma patients with renal failure.
Ashraf Badros,Bart Barlogie,Eric R. Siegel,Jennifer Roberts,Candi Langmaid,Maurizio Zangari,Raman Desikan,Mary Jo Shaver,Athanasios Fassas,Scott A. McConnell,Firas Muwalla,Yousri M. Barri,Elias Anaissie,Nikhil C. Munshi,Guido Tricot +14 more
TL;DR: The role of auto-SCT early in the disease course and benefits of tandem SCT require further evaluation in the setting of multiple myeloma patients with renal failure as discussed by the authors.